The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Next-generation CAR-T strategies aim to improve outcomes in large B-Cell lymphoma
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the future of CAR-T cell therapy and the next-generation innovations that may help overcome treatment failure and improve long-term outcomes for large B-cell lymphoma (LBCL). He highlights the potential advantages of rapid manufacturing, dual-targeted CAR-T constructs, and fresh product infusion, emphasizing how innovations beyond CAR design alone could enhance both the delivery and efficacy of CAR-T therapies. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think CAR-T is a really interesting field. Each CAR construct is unique. And not only is the construct unique, but how you manufacture it is unique. So some of the things I didn’t mention about our platform is we use rapid manufacturing, which might be another reason that patients do well with this construct is you get a more naive CAR-T cell product. And with the more naive product you might get better expansion, better kinetics, better response...
I think CAR-T is a really interesting field. Each CAR construct is unique. And not only is the construct unique, but how you manufacture it is unique. So some of the things I didn’t mention about our platform is we use rapid manufacturing, which might be another reason that patients do well with this construct is you get a more naive CAR-T cell product. And with the more naive product you might get better expansion, better kinetics, better response. And so we sort of incorporate a lot of different aspects into this package. Short manufacturing, dual-targeted construct, and also we do a fresh infusion. So we don’t cryopreserve the product, we actually administer the CAR-T cells fresh. And so together this package could be ways to improve upon current CAR-T cell therapies by innovating not just the construct, but the other pieces around it. And so we think that these things are going to be important to both help the delivery of CAR-T and improve the efficacy of this treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
